Literature DB >> 29562224

PARP (Poly(ADP-Ribose) Polymerase) Inhibitors in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis of Randomized Controlled Trials.

Samer Al Hadidi, Ahmed Aburahma, Sunil Badami, Sunil Upadhaya.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29562224     DOI： 10.1159/000486418

Source DB:  PubMed          Journal:  Oncol Res Treat        ISSN： 2296-5270            Impact factor:   2.825


× No keyword cloud information.
  4 in total

Review 1.  Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.

Authors:  Abigail Tattersall; Neil Ryan; Alison J Wiggans; Ewelina Rogozińska; Jo Morrison
Journal:  Cochrane Database Syst Rev       Date:  2022-02-16

2.  Effect of molecular targeted agents in chemotherapy for treating platinum-resistant recurrent ovarian cancer: A systematic review and meta-analysis.

Authors:  Luting Liu; Wanchun Xiong
Journal:  Medicine (Baltimore)       Date:  2021-08-13       Impact factor: 1.817

Review 3.  Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.

Authors:  Hongyan Cheng; Junjun Yang; Huixin Liu; Yang Xiang
Journal:  Arch Gynecol Obstet       Date:  2021-05-21       Impact factor: 2.344

4.  Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.

Authors:  Fengping Shao; Jun Liu; Yaoyun Duan; Li Li; Liqun Liu; Cai Zhang; Shanyang He
Journal:  Biosci Rep       Date:  2020-03-27       Impact factor: 3.840
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.